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Introduction: Pemetrexed is an effective and a tolerable drug in
advanced non-small cell lung cancer (NSCLC). This study sought to
ascertain maximum tolerated dose (MTD) and phase II dose of
carboplatin or cisplatin given with pemetrexed and concurrent chest
radiation therapy (CRT) in locally advanced NSCLC.
Methods: Eligible, previously untreated patients were enrolled with
the initial intent of establishing the MTD of both weekly cisplatin or
carboplatin combined with pemetrexed 500 mg/m2 every 3 weeks
and concurrent CRT in an alternating, two arm, phase I trial.
Secondary objectives included response rate and toxicity. The pro-
tocol was subsequently amended to establish the safety of planned
phase II doses of cisplatin or carboplatin combined with pemetrexed
500 mg/m2 given every 3 weeks  3 cycles with CRT.
Results: Patients received pemetrexed combined with carboplatin
area under curve  2 (n  9), cisplatin 30 mg/m2 (n  9), or
cisplatin 75 mg/m2 (n  4). One dose-limiting toxicity occurred in
both the carboplatin and in the cisplatin 30 mg/m2 cohorts. No
dose-limiting toxicities occurred in the cisplatin 75 mg/m2 cohort.
Because these are standard doses without radiation therapy in lung
cancer, there was no further dose escalation. Partial response rates
were 11% (carboplatin) and 46% (combined cisplatin). Stable dis-
ease rates were 33% (carboplatin) and 46% (combined cisplatin).
Two patients receiving carboplatin experienced disease progression.
Conclusions: The MTD of cisplatin combined with pemetrexed was
not reached. Based on these and Cancer and Leukemia Group B
30407 results, pemetrexed with either carboplatin or cisplatin at full
systemic doses with CRT seems to be well tolerated. A multicenter,
randomized phase II trial of both regimens is underway.
Key Words: Pemetrexed, Non-small cell lung cancer, Chemoradia-
tion, Alimta.
(J Thorac Oncol. 2010;5: 1391–1396)
Treatment of non-small cell lung cancer (NSCLC) has under-gone many refinements during the last several decades.
These advancements have prolonged survival and increased
response rates, but have had negligible impact on long-term,
5-year survival, which has remained fairly constant at 15% for
all disease stages.1,2 During this time, multimodality therapy has
been a mainstay for treatment of local and regional disease.
Surgery, radiotherapy, and chemotherapy have been combined
in multiple ways in an effort to maximize response rate and
survival. Newer drug combinations, especially in advanced dis-
ease, have comparable response and survival rates with varying
toxicity profiles.3 These newer agents are typically paired with
either cisplatin or carboplatin and include paclitaxel, docetaxel,
vinorelbine, and gemcitabine.
Efforts to improve local control of the primary tumor have
been encouraging. However, distant failure continues to impede
any significant impact on overall survival (OS). Recent efforts to
target this seeming therapeutic paradox have led to investiga-
tions of radiation sensitizers, neoadjuvant regimens, and consol-
idation strategies. One of the newer agents with potential for
incorporation into all aspects of therapy is the multitargeted
antifolate, pemetrexed. Unlike its predecessors, 5-FU and meth-
otrexate, pemetrexed has the ability to interfere with the synthe-
sis of both pyrimidines and purines.4–6 Pemetrexed is US Food
and Drug Administration approved in combination with cispla-
tin for the treatment of inoperable malignant mesothelioma and
for first-line treatment of advanced or metastatic nonsquamous
NSCLC. Pemetrexed is approved as a single agent for second-
line treatment of advanced or metastatic nonsquamous NSCLC
and also as maintenance therapy for patients with nonsquamous
NSCLC who have responded to chemotherapy.
In addition to its activity, pemetrexed has shown promise
for its combinability with platinum and nonplatinum agents as
well as with radiation therapy, in both concurrent and sequential
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settings, in which it can be administered and tolerated at full
systemic doses. Pemetrexed is synergistic with both carboplatin
and cisplatin in preclinical models and in pleural mesothelioma.7
Multiple phase II trials of pemetrexed plus cisplatin or carbo-
platin have shown activity in advanced NSCLC with encourag-
ing response rates for both combinations.8–11
The activity of pemetrexed as a radiosensitizer has been
studied in preclinical investigations with animals and was shown
to be radiotherapy enhancing.12 Platinum agents have demon-
strated enhancement of radiation when given concomitantly, but
have exhibited unacceptable toxicity when used with full-dose
combination chemotherapy regimens plus radiotherapy. The
acceptable tolerance profile of pemetrexed in combination with
platinum agents led to interest in combining these agents with
radiation to treat locally advanced NSCLC. The toxicity and
safety of combining pemetrexed and either cisplatin or carbo-
platin at full systemic doses with concurrent radiation therapy
have not been reported. Previous trials combining pemetrexed
with either carboplatin or cisplatin in combination with radiation
therapy in locally advanced NSCLC have helped to establish the
maximum tolerated dose (MTD) of pemetrexed, but did not
evaluate the MTD of either carboplatin or cisplatin.13,14
Systemic relapse continues to be the most common cause
of death in patients with locally advanced NSCLC after chemo-
radiation. The Southwest Oncology Group evaluated the role of
consolidation chemotherapy with docetaxel in a single-arm
phase II trial that showed a median survival of 26 months and
3-year survival of 37%, by far the best results seen in stage III
NSCLC treated with definitive chemoradiation.15 However,
these results failed to hold up in a randomized phase III study by
Hanna et al.,16 who reported a high incidence of grade 3 or 4
neutropenia in patients who were randomly assigned to the
consolidation arm. Pemetrexed has a favorable toxicity profile
compared with docetaxel, with less grade 3 or 4 neutropenia and
febrile neutropenia, as seen in a randomized, phase III trial.16
This suggests that pemetrexed may be better suited for consol-
idation therapy given its efficacy and tolerability.
This multicenter, phase I/randomized phase II trial was
designed to target both cisplatin and carboplatin at full systemic
doses combined with pemetrexed and concurrent chest radiation
therapy (CRT) in a dose-finding study, with a planned pem-
etrexed consolidation to follow. After the phase I portion, the
recommended phase II doses were planned to be incorporated
into a randomized phase II trial of pemetrexed plus carboplatin
or cisplatin followed by pemetrexed consolidation, in an attempt
to improve 2-year survival for patients with inoperable but
favorable prognosis stage IIIA/B NSCLC. The phase I portion of
the trial enrolled patients from 2005 to 2007, and results are
reported in this article.
PATIENTS AND METHODS
Eligibility Criteria
Before study entry, patients underwent baseline computed
tomography (CT) with tumor measurements, physical examina-
tion, Eastern Cooperative Oncology Group performance status,
complete blood count, and serum chemistries. Positron emission
tomography (PET) scan and brain imaging (magnetic resonance
imaging or CT with contrast) were required on all patients.
Adults aged 18 years or older, with histologic or cytologic
confirmation of NSCLC and unresectable stage IIIA or IIIB
disease determined to be suitable for combined chemoradiother-
apy by a medical and radiation oncologist were eligible candi-
dates. Patients with hematogenous metastasis, malignant pleural
effusion, prior chemotherapy, thoracic radiotherapy, and/or sur-
gical resection were not eligible. Other eligibility criteria in-
cluded Eastern Cooperative Oncology Group performance status
0 to 1 at baseline; unintentional weight loss less than 10% in the
3 months before diagnosis; preregistration forced expiratory
volume 1 more than 1000 ml; adequate bone marrow (hemo-
globin 8 g/dl, absolute neutrophil count 1500/l, and plate-
lets 100,000/l), renal (calculated creatinine clearance 45
ml/min), and hepatic (serum bilirubin 1.5 mg/dl, aspartate
transaminase, alanine transaminase, and alkaline phosphatase
3 times the institutional upper limit of normal) functions.
Patients were excluded if they had myocardial infarction within
the preceding 6 months or other symptomatic heart disease. This
study was approved by the institutional review boards at all
participating institutions and was conducted in accordance with
the Declaration of Helsinki and Good Clinical Practice guide-
lines. All patients provided written informed consent before
undergoing any study procedure or receiving any study treat-
ment.
Study Design
This trial was planned as a phase I stepwise design,
followed by randomized phase II trial. The primary end point of
the phase I portion of the study was to determine the MTD and
recommended phase II dose of carboplatin or cisplatin in com-
bination with pemetrexed and concurrent CRT. After establish-
ing the MTD of both carboplatin and cisplatin in combination
with pemetrexed, the phase II portion of the study planned to
evaluate 2-year survival using both these regimens. The phase I
dose-escalation portion of the study was originally designed to
enroll cohorts of six patients each, beginning with arm A (Figure
1). After the initial six patients were enrolled, enrollment was to
begin on arm B, then on the next higher arm A dose level as a
part of planned dose escalation for each arm. After the release of
other early phase trial results detailing the MTD of carboplatin
area under curve (AUC) 5 in combination with pemetrexed
(Cancer and Leukemia Group B [CALGB] 30407) showed
feasibility and reasonable tolerability,17 the protocol was subse-
quently amended (September 2006). Thus, the previously
planned dosing levels 2A and 3A were not pursued, and the
design of the trial was modified to establish pemetrexed with
carboplatin AUC 5 and pemetrexed with cisplatin 75 mg/m2
given every 3 weeks as the phase II doses and to explore the
possible systemic dose of these agents with concurrent CRT in
locally advanced NSCLC. In addition, the protocol was simul-
taneously amended to increase the concurrent CRT total dose to
64 to 68 Gy from 63 Gy in alignment with other ongoing trials,
investigating similar combination therapies for stage III NSCLC.
Treatment Plan
Eligible patients received pemetrexed 500 mg/m2 on days
1, 22, and 43 with either carboplatin or cisplatin as detailed in
Table 1 concurrent with CRT. Folic acid and vitamin B12
supplementation were given to reduce hematologic toxicity
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associated with pemetrexed therapy. Radiation therapy was
administered at a dose of 2 Gy daily for 5 days a week, to a total
dose of 63 to 68 Gy depending on institutional preference. CT
imaging was required for treatment planning to define gross
tumor volume (GTV), and the use of four-dimensional treatment
planning was encouraged. GTV was defined as primary tumor
and clinically enlarged lymph nodes (1 cm short axis on CT or
standardized uptake value 3 on PET). Use of diagnostic
PET/CT was suggested for help with GTV definition. Clinical
treatment volume was defined as GTV plus a 0.5 to 1 cm margin
as appropriate to account for microscopic tumor extension.
Elective treatment of the mediastinum or supraclavicular fossa
was not allowed. Planning target volume included the clinical
treatment volume plus a margin to account for motion, typically
1.0 to 1.5 cm in the superior-inferior dimensions of the field.
Treatment planning was performed with a combination of co-
planar or noncoplanar 3D conformal fields shaped to the plan-
ning target volume with restriction of dose to the normal tissues.
Intensity-modulated radiotherapy treatment planning was al-
lowed on this protocol. Normal tissue constraints were priori-
tized for treatment planning and included limiting maximum
dose to the spinal cord48 Gy; volume of both lungs receiving
20 Gy (V20)37%; recommended mean dose to the esophagus
less than 34 Gy; maximum dose to the brachial plexus less than
66 Gy; and heart dose limited to 60 Gy to less than 1/3, 45 Gy
less than 2/3, and 40 Gy less than whole heart.
Patients without evidence of progressive disease on initial
follow-up CT scan were to receive consolidation chemotherapy
of pemetrexed 500 mg/m2 every 21 days for three cycles,
beginning 3 to 5 weeks after completion of chemoradiation.
Folic acid and vitamin B12 supplementation were continued.
Routine use of colony-stimulating factor (CSF) was not permit-
ted during this study, but patients with an absolute neutrophil
count less than 0.5 109/liter, neutropenic fever, or documented
infection while neutropenic were allowed to receive granulocyte
CSF (G-CSF) during the consolidation portion of treatment, per
the American Society of Clinical Oncology guidelines.
Follow-Up
Toxicity was assessed weekly during chemoradiotherapy,
at 3 weeks after completion of chemoradiotherapy, every 3
weeks during consolidation therapy, at 1 month after completion
of consolidation therapy, and then every 2 to 3 months until a
total of 24 months after start of study therapy or until progressive
disease. Toxicities were graded according to the National Cancer
Institute Common Terminology Criteria for Adverse Events
version 3.0. Assessment of late effects of radiation therapy was
performed 90 days after the start of radiation and was graded
using the Radiation Therapy Oncology Group Late Morbidity
Scoring Schema.
ARM A
Dose 
Level
Pemetrexed 
mg/m2
q 21 days x 3 cycles
Carboplatin 
AUC
days 1,8,22,29,43
Patients
n
1A 500 2 6
ARM B
Dose 
Level
Pemetrexed 
mg/m2
q 21 days x 3 cycles
Cisplatin
mg/m2
days 1,8,22,29,43
Patients
n
1B 500 30 6
Dose 
Level
Pemetrexed 
mg/m2
q 21 days x 3 cycles
Carboplatin
AUC
days 1,8,22,29,43
Patients
n
2A* 500 2.5 6
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Dose 
Level
Pemetrexed 
mg/m2
q 21 days x 3 cycles
Cisplatin
mg/m2
days 1,8,22,29,43
Patients
n
2B 500 35* 6
Dose 
Level
Pemetrexed 
mg/m2
q 21 days x 3 cycles
Carboplatin
AUC
days 1,8,22,29,43
Patients
n
3A* 500 3 6
Dose 
Level
Pemetrexed 
mg/m2
q 21 days x 3 cycles
Cisplatin
mg/m2
days 1,8,22,29,43
Patients
n
3B* 500 40 6
*Dose level cancelled by protocol amendment
*Dose level cancelled by protocol amendment *Dose level cancelled by protocol amendment
*Amended to75 mg/m2 on days 1,22,43
C
O
N
S
O
L
I
D
A
T
I
O
N
FIGURE 1. Study design and dose levels. The study design is shown. The solid black arrows represent the flow of the original
study design. The trial was subsequently amended as follows: after completion of dose level 1B and a 30-day evaluation period, the
trial advanced to dose level 2B at a cisplatin dose of 75 mg/m2 q 21 days  3 cycles. Dose levels 2A, 3A, and 3B were can-
celled. The dotted black arrows represent the amended flow of the trial. Beginning on day 1 of cycle 1 (after the chemother-
apy infusions), radiotherapy was administered in 2 Gy/d fractions  5 days/wk until the total dose reached 63 to 68 Gy dur-
ing approximately 6 to 7 weeks. Consolidation chemotherapy began 3 weeks after completion of chemoradiotherapy and
consisted of pemetrexed 500 mg/m2 q 21 days  3 cycles. AUC, area under curve; n, number; q, every.
TABLE 1. Dosing Cohorts
Treatment No. of Patients
Pemetrexed 500 mg/m2  Carboplatin AUC 2 9
Pemetrexed 500 mg/m2  Cisplatin 30 mg/m2 9
Pemetrexed 500 mg/m2  Cisplatin 75 mg/m2 4
AUC, area under the curve.
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For the phase I portion of the study, dose-limiting toxicity
(DLT) was defined as any of the following events occurring
during the entire radiation treatment course, including a 2-week
recovery period after its completion: grade 4 neutropenia
(0.5 109/liter) lasting more than 7 days; febrile neutropenia
or grade 3 neutropenia with fever more than 38.5°C; grade 4
thrombocytopenia lasting more than 7 days; grade 3 thrombo-
cytopenia with grade 2 bleeding; grade 4 nonhematologic
toxicity (excluding nausea, vomiting, and transaminase eleva-
tions); or grade4 pulmonary or esophageal toxicity (radiation-
related pneumonitis or esophagitis). MTD was originally defined
as the occurrence of two DLTs within one dose cohort. The
protocol was subsequently amended to establish the toxicity of
the planned phase II doses of cisplatin and carboplatin in
combination with pemetrexed.
Response was assessed by RECIST with CT scans. A
postchemoradiation CT scan was obtained at least 7 to 10 days
before consolidation therapy. CT scans were then repeated after
cycle 3 of chemotherapy, at 30 days after completion of all
therapy, then every 2 months for three assessments, then every
3 months until disease progression, or 24 months from initiation
of study therapy, whichever came first. Best overall response
was defined as the best response recorded from the start of
treatment until disease progression or recurrence.
Statistical Analysis
Patient demographics, tumor response rate, and toxicity
were summarized using descriptive statistics in each of the two
cohorts (carboplatin/pemetrexed and combined cisplatin/pem-
etrexed). Median OS and median progression-free survival were
estimated using the Kaplan-Meier method for the whole study
population.
RESULTS
Twenty-two patients were enrolled in three cohorts
between July 2005 and March 2007 (Table 1). One DLT
occurred in the carboplatin AUC 2 arm and one in the
cisplatin 30 mg/m2 arm, prompting enrollment of three addi-
tional patients in these two cohorts. Four patients were
enrolled to the cohort that included the planned phase II dose
of cisplatin (75 mg/m2) in combination with pemetrexed, in
which no DLTs were seen. The phase I portion of the trial
was completed after a total of 22 patients were enrolled, after
which the phase II portion of the trial commenced. Patient
demographics and pretreatment forced expiratory volume, 1
minute values by arm are listed in Table 2. The median
duration of treatment was 16 weeks. A total of 16 patients
(73%) completed initial planned chemoradiation. This in-
cluded 6 of 9 patients (67%) who received carboplatin/
pemetrexed, 6 of 9 patients (67%) who received cisplatin 30
mg/m2/pemetrexed, and all four patients who received cis-
platin 75 mg/m2/pemetrexed. Fourteen patients (64%) re-
ceived at least one cycle of consolidation pemetrexed and 10
patients (45%) completed all three cycles of consolidation
pemetrexed as planned, including 3 of 9 patients (33%)
receiving carboplatin/pemetrexed, 4 of 9 patients (44%) re-
ceiving cisplatin 30 mg/m2/pemetrexed, and 3 of 4 patients
(75%) receiving cisplatin 75 mg/m2/pemetrexed. Reasons for
not proceeding to consolidation chemotherapy included pa-
tient decision,1 adverse event,3 investigator decision,1 pro-
gressive disease,2 and death.1 Mean radiation dose for pa-
tients who completed therapy and those who did not was 72
Gy and 33 Gy, respectively.
Toxicity
Observed toxicities by treatment arm are listed in Table
3. The most common hematologic toxicity was neutropenia,
whereas fatigue was the most common nonhematologic tox-
icity. Two DLTs occurred, a treatment-related pneumonia
that resulted in death (grade 5) in the carboplatin/pemetrexed
cohort and a treatment-related hemoptysis leading to death
(grade 5) in the cisplatin 30 mg/m2 per pemetrexed cohort.
Grade 3 or 4 hematologic toxicity was seen in 7 of 22 patients
(32%), including 3 of 13 patients who received cisplatin
versus 4 of 9 patients who received carboplatin. Grade 3
radiation pneumonitis was seen in only 1 of 22 patients (5%)
and occurred in the carboplatin cohort. No grade 3 or 4
esophagitis was observed in any of the patients enrolled.
Late toxicity graded by the Radiation Therapy Oncol-
ogy Group Late Morbidity Assessment was minimal in this
trial. Of patients receiving carboplatin/pemetrexed, one pa-
tient reported grade 2 pulmonary toxicity and grade 1 late
toxicity in the brain and mucous membranes, two patients
reported grade 1 pulmonary toxicity, and one patient reported
grade 1 esophageal toxicity. Of patients receiving cisplatin/
pemetrexed, one patient reported grade 1 toxicity of both the
TABLE 2. Patient Demographics
Pemetrexed/
Carboplatin
Pemetrexed/
Cisplatin
Age, yr
Median 62 60
Range 46–74 43–84
Sex, n
Female 2 4
Male 7 9
Race, n
White 8 7
Black 1 3
Hispanic 0 1
Asian 0 2
ECOG PS, n
0 4 5
1 5 8
Stage, n
IIIA 5 7
IIIB 4 6
Histology
Adenocarcinoma 6 2
Squamous cell 1 3
Othera 6 4
FEV 1 (L)
Mean 2.26  0.9 2.27  0.7
a Includes large cell, bronchioalveolar, and poorly differentiated histologies.
ECOG PS, Eastern Cooperative Oncology Group performance status; FEV1, forced
expiratory volume, 1 s; n, number.
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lung and esophagus, and one patient had grade 1 pulmonary
toxicity.
Treatment Outcome
Partial response was seen in 11% (95% confidence
interval [CI]: 0.3–48.3%) of patients in the carboplatin cohort
and in 46% (95% CI: 16.8–76.6%) of patients in the com-
bined cisplatin cohorts. Stable disease was seen in 33% (95%
CI: 7.5–70.1%) and in 46% (95% CI: 16.8–76.6%) of pa-
tients in the carboplatin and cisplatin cohorts, respectively.
Two patients in the carboplatin cohort had disease progres-
sion. Median progression-free survival of all the 22 patients
enrolled was 7.2 months (95% CI: 5.36–16.26%), with me-
dian OS of 21.6 months (95% CI: 7.4, not estimable).
DISCUSSION
Concurrent chemoradiation is the current standard of
care for most patients with unresectable locally advanced
NSCLC.1,2 Most patients receive a platinum doublet in com-
bination with radiation. This phase I study attempted to
establish the safety of either carboplatin or cisplatin at esca-
lating doses in combination with pemetrexed and CRT as
treatment of locally advanced NSCLC. Pemetrexed is a
multitargeted antifolate that has shown efficacy in advanced
NSCLC in combination with platinum agents.5,6 Its ease of
combinability with either cisplatin or carboplatin for admin-
istration at full systemic doses makes it promising as a
potential systemic agent in combination with radiation ther-
apy as a means to improve the efficacy of combined modality
therapy in locally advanced NSCLC, while reducing the
toxicity profile that often prevents completion of therapy.
The efficacy of pemetrexed in advanced NSCLC has
been shown both as a single agent and in phase II trials in
combination with cisplatin or carboplatin.8–11 Response rates
were promising, ranging from 28 to 50%, prompting evalu-
ation in a phase III trial of pemetrexed as single-agent,
second-line therapy in advanced NSCLC. This trial con-
ducted by Hanna et al.16 showed pemetrexed to have equiv-
alent efficacy to docetaxel in the second-line setting, with a
favorable toxicity profile, including significantly reduced
rates of grade 3 or 4 neutropenia, febrile neutropenia, hospi-
talizations, alopecia, and use of growth factor support. A
phase III study conducted in Europe evaluated the combina-
tion of cisplatin and pemetrexed as first-line therapy for
advanced NSCLC and showed it to be equivalent to cisplatin
and gemcitabine, with superior OS for cisplatin/pemetrexed
in nonsquamous cell histologies.9 The toxicity profile for the
pemetrexed combination was again favorable, with reduced
rates of grade 3 or 4 neutropenia, anemia, thrombocytopenia,
febrile neutropenia, and alopecia.
Given its favorable toxicity profile, this study investi-
gated the use of pemetrexed in combination with platinum
agents and concurrent CRT for treatment of locally advanced
NSCLC. Preclinical studies suggested synergistic activity of
pemetrexed and radiation in lung cancer cell lines.12 Several
institutions initiated parallel studies that evaluated combining
pemetrexed, radiotherapy, and other targeted or cytotoxic
agents. Studies before this helped to establish the MTD of
pemetrexed as 500 mg/m2 when combined with radiation and
either carboplatin or cisplatin.13,14,18 Data from the study by
Seiwert et al. established tolerance of pemetrexed 500 mg/m2
either as a single agent or in combination with carboplatin
and concurrent radiotherapy in patients with locally advanced
or locally symptomatic metastatic NSCLC. The dose of
pemetrexed in this setting was capped at 500 mg/m2 after it
was established as the dose for second-line treatment in
NSCLC by Hanna et al.16 MTD was not established in the
phase 1 trial by Seiwert et al.,14 with only two DLTs seen:
one grade 4 esophagitis with single-agent pemetrexed 500
mg/m2, and one grade 3 esophagitis with pemetrexed 500
mg/m2 and carboplatin AUC 6. Reasonable rates of hemato-
logic toxicity, radiation pneumonitis, and esophagitis were
seen, prompting additional investigation of this combination
in locally advanced patients in a phase II setting. The
CALGB initiated a randomized phase II study evaluating
pemetrexed 500 mg/m2 in combination with carboplatin AUC
5 and thoracic radiation with or without cetuximab for pa-
tients with unresectable stage III NSCLC. Toxicity of this
combined therapy, presented in abstract form at the 2008
American Society of Clinical Oncology Annual Meeting,
showed acceptable tolerance of this regimen at the above
doses.17 Preliminary efficacy, presented at the 2009 Amer-
ican Society of Clinical Oncology Annual Meeting,
showed an overall response rate of 73% and a median OS
of 22.3 months in patients who received carboplatin and
pemetrexed with radiation therapy.19 Two other studies
evaluated the combination of cisplatin with pemetrexed
and radiation; these studies showed acceptable toxicity and
encouraging response rates.13,20
This phase I trial attempted to establish the MTD of
both cisplatin and carboplatin in combination with pem-
etrexed 500 mg/m2 with concurrent CRT for stage IIIA/IIIB
NSCLC. Based on the results of this trial and the CALGB
TABLE 3. Toxicity by Treatment Arm
Cohort Dose Level
Total
Patients, n
Non-Heme
Grade 1/2, n
Heme
Grade 1/2, n
Non-Heme
Grade 3/4, n
Heme
Grade 3/4, n DLT n/Event
1A Carboplatin AUC  2 9 9 5 6 4 1/Pneumocystis pneumonia, grade 5
1B Cisplatin 30 mg/m2 9 9 4 6 3 1/Hemoptysis, grade 5
2B Cisplatin 75 mg/m2a 4 3 2 3 0 0
Total 22 21 11 15 7 2
a Adverse events records were not available for one patient in the 2B cohort.
AUC, area under curve; Heme, hematologic; DLT, dose-limiting toxicity; n, no. of patients.
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30407 trial results, we conclude that pemetrexed in combi-
nation with either carboplatin or cisplatin at full systemic
doses and concurrent radiation seems to be well tolerated.
Although this was a phase I study, efficacy is reported for
informational purposes, with overall response rates of 11%
for the carboplatin cohort and 46% for the cisplatin cohort.
These rates were slightly lower than other available data on
concurrent chemoradiation with pemetrexed.20 These com-
parisons are limited by dose differences in the tested regi-
mens. Despite a low response rate, the median OS was
comparable with historical controls for combined modality
therapy in this patient population.2,21
This trial was opened before publication of the data
from Europe regarding the benefit of pemetrexed in treatment
of nonsquamous cell histologies, and four patients enrolled in
the study did have squamous cell carcinoma possibly affect-
ing overall outcome considering that pemetrexed has shown
less efficacy compared with other agents for squamous cell
carcinoma in the metastatic setting.9 The phase II portion of
this study was amended to include only nonsquamous cell
histologies. The data regarding the heterogeneous response of
NSCLC to therapeutic agents will likely lead to more indi-
vidualized treatment of NSCLC in the future to choose the
most effective regimens for these patients. Another limitation
of this study is the percentage of patients who completed the
planned chemoradiation course (73%). Given the small size
of the trial and suboptimal proportion of patients who com-
pleted initial chemoradiation, the response rates reported here
should be considered with prudence. The randomized phase
II portion of this study is almost complete and will provide
more appropriate data for interpretation of efficacy of these
two chemotherapy combinations. Furthermore, a phase III
trial evaluating pemetrexed, cisplatin, and radiation followed
by consolidation pemetrexed versus cisplatin, etoposide, and
radiation (PROCLAIM study) is actively enrolling patients.
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